Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., March 12, 2025 /PRNewswire/ — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven by obesity, today announced the publication of results...